Skip to main content
  • Bookmarks
  • Register
  • Login

NIH OIR/OTT Logo

Main Menu

  • Partnerships

    Partnerships

    These links provide access to the information that is commonly needed for companies or organizations interested in partnering with NIH. The information here covers the process from researching available technologies through fees associated.

    • Overview
    • Opportunities
    • Featured Technologies
    • Collaboration / CRADAs
    • Licensing Process
    • Forms / Model Agreements
    • Startups
    • Non-Profits
    • License Materials
    • Licensing FAQs
    • Business Opportunities
    • Product Showcase
    • Product Pipeline
    • Federal Register Notices

    The NIH cannot commercialize its discoveries even with its considerable size and resources — it relies instead upon partners. Typically, a royalty-bearing exclusive license agreement with the right to sublicense is given to a company from NIH to use patents, materials, or other assets to bring a therapeutic or vaccine product concept to market.

  • Royalties

    Royalties

    Information for inventors and licensees on the administration of royalties.

    • Information for NIH Inventors
    • Information for Licensees
    • License Notices / Reports
    • Royalty Coordinators
    • NIH Payment Center
    • CDC Payment Center

    Each year, hundreds of new inventions are made at NIH and CDC laboratories. Nine NIH Institutes or Centers (ICs) transfer NIH and CDC inventions through licenses to the private sector for further research and development and eventual commercialization.

  • Reports

    Reports

    These links provide access to reports tracking the success of NIH licensed products.

    • Annual Reports
    • Tech Transfer Statistics
    • Tech Transfer Metrics
    • Commercial Outcomes
    • HHS License-Based Vaccines & Therapeutics
    • Public Health & Economic Impact Study
    • Stories of Discovery
    • Chen Lecture Videos
    • NIH Patents and Active Patent Commercialization Licenses
    • Media Room
    • Tech Transfer Newsletters
    • NIH Patents and Patent Applications

    The NIH, CDC and FDA Intramural Research Programs are exceptionally innovative as exemplified by the many products currently on the market that benefit the public every day. Reports are generated from the commonly tracked metrics related to these products.

  • Resources

    Resources

    These links provide resources to those interested in the technology transfer activities at NIH.

    • Forms and Model Agreements
    • License Notices / Reports
    • Video Library
    • Inventor Resources
    • Presentations & Articles
    • FAQs
    • RSS Feeds
    • Inventor Showcase

    Past videos, lectures, presentations, and articles related to technology transfer at NIH are kept and made available to the public. These topics range from general technology transfer information to processes specific to NIH.

  • Policy & Regulations

    Policies & Regulations

    These links provide access to the policies and regulations surrounding partnering or collaborating with NIH.

    • Freedom of Information Act (FOIA)
    • PHS Technology Transfer Policy
    • Policies & Reports
    • Useful Links

    If a company would like to acquire rights to use or commercialize either an unpatented material, or a patented or patent-pending invention, a license is required. There are numerous policies and regulations surrounding the transfer or a technology from the NIH to a company or organization.

  • About

    About Us

    These links provide information about the Office of Technology Transfer.

    • Contact Us
    • Staff Directory
    • Management
    • FAQs
    • HHS Tech Transfer Offices & Contacts
    • Careers in Tech Transfer
    • Location & Directions
    • Feedback

    The NIH Office of Technology Transfer (OTT) plays a strategic role by supporting the patenting and licensing efforts of our NIH ICs. OTT protects, monitors, markets and manages the wide range of NIH discoveries, inventions, and other intellectual property as mandated by the Federal Technology Transfer Act and related legislation.

Breadcrumb

  1. Home
  2. Taxonomy
  3. Term
  4. NCI

METHOD AND SYSTEM FOR IDENTIFYING ACID-FAST STRUCTURES IN SLIDE- MOUNTED BIOLOGICAL SPECIMENS

  • Read more about METHOD AND SYSTEM FOR IDENTIFYING ACID-FAST STRUCTURES IN SLIDE- MOUNTED BIOLOGICAL SPECIMENS
US Application 60/066,234
Filed on 1997-11-20

ASPIRIN METABOLITES AS PROTECTORS AGAINST OXIDATIVE STRESS AND CHEMOTHERAPHY DRUG TOXICITY

  • Read more about ASPIRIN METABOLITES AS PROTECTORS AGAINST OXIDATIVE STRESS AND CHEMOTHERAPHY DRUG TOXICITY
US Application 60/039,375
Filed on 1997-03-20

HYDRAZIDES, A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS, AS POTENTIAL ANTI-AIDS AND ANTI-CANCER DRUGS

  • Read more about HYDRAZIDES, A NOVEL CLASS OF HIV-1 INTEGRASE INHIBITORS, AS POTENTIAL ANTI-AIDS AND ANTI-CANCER DRUGS
US Application 60/040,198
Filed on 1997-03-06

Inhibition of Signal Transduction by the Binding of Non-Phosphorylated Compositions

  • Read more about Inhibition of Signal Transduction by the Binding of Non-Phosphorylated Compositions
US Application 60/021,858
Filed on 1996-07-16

ACRIDONE-DERIVED COMPOUNDS USEFUL AS ANTINEOPLASTIC AND ANTIRETROVIRAL AGENTS

  • Read more about ACRIDONE-DERIVED COMPOUNDS USEFUL AS ANTINEOPLASTIC AND ANTIRETROVIRAL AGENTS
US Application 60/035,050
Filed on 1997-01-22

STABILIZATION OF AN IMMUNOGLOBULIN FRAGMENT BY BASE-LOOP INTERCONNECTION AND CHAIN PERMUTATION

  • Read more about STABILIZATION OF AN IMMUNOGLOBULIN FRAGMENT BY BASE-LOOP INTERCONNECTION AND CHAIN PERMUTATION
US Application 60/040,848
Filed on 1997-03-17

NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE

  • Read more about NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE
US Application 60/038,509
Filed on 1997-02-25

ENHANCED SUPPRESSION OF HIV-1 BY THE COMBINATION OF CYTIDINE NUCLEOSIDE ANALOGUES AND CTP SYNTHASE INHIBITORS.

  • Read more about ENHANCED SUPPRESSION OF HIV-1 BY THE COMBINATION OF CYTIDINE NUCLEOSIDE ANALOGUES AND CTP SYNTHASE INHIBITORS.
US Application 60/033,918
Filed on 1997-01-21

COMPOUNDS FORMED BY THE REACTION OF NITRIC OXIDE WITH AMIDINES AND ENAMINES AS PHARMACEUTICAL AGENTS

  • Read more about COMPOUNDS FORMED BY THE REACTION OF NITRIC OXIDE WITH AMIDINES AND ENAMINES AS PHARMACEUTICAL AGENTS
US Application 60/051,690
Filed on 1997-07-03

RECOMBINANT IMMUNOTOXINS TARGETED TO CD-22 BEARING CELLS AND TUMORS RFB4 IMMUNOTOXINS EXHIBIT POTENT CYTOTOXIC ACTIVITY FOR CD22 BEARING C

  • Read more about RECOMBINANT IMMUNOTOXINS TARGETED TO CD-22 BEARING CELLS AND TUMORS RFB4 IMMUNOTOXINS EXHIBIT POTENT CYTOTOXIC ACTIVITY FOR CD22 BEARING C
US Application 60/041,437
Filed on 1997-03-20

Pagination

  • First page « First
  • Previous page ‹‹
  • …
  • Page 215
  • Page 216
  • Page 217
  • Page 218
  • Page 219
  • Page 220
  • Page 221
  • Page 222
  • Page 223
  • …
  • Next page ››
  • Last page Last »
Subscribe to NCI
NIH White Technology Transfer Logo

Return to Top

  • About
  • Privacy Notice
  • Accessibility
  • Web Policies & Notices
  • Open Data
  •  
  • For NIH Staff Only
  • HHS
  • NIH
  • HHS Vulnerability Disclosure
  • Connect
  • Twitter
  • LinkedIn
  • Contact
  • Feedback

Office of Technology Transfer, Office of Intramural Research, National Institutes of Health